Health Care • Biotechnology: Pharmaceutical Preparations
$2.51 ▼ -0.17
(-6.34%)
MKT CAP: $177.0M • VOL: 79.7K
52W L $1 52W H $5
ADAG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.7M | $103.2K | $18.1M |
| YoY Revenue Growth % | +7332.8% | -99.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$21.4M | -$36.0M | -$23.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$17.6M | -$33.4M | -$18.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.7M | -$29.7M | -$28.5M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$15.7M | -$29.7M | -$28.5M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $74.5M | $85.2M | — |
| Total Debt (Short + Long Term) | $1.1M | $417.3K | — |
| Total Stockholders' Equity | $35.3M | $50.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ADAG.